InflaRx Reports Encouraging Post-Hoc Analyses for Vilobelimab in Pyoderma Gangrenosum Despite Phase 3 Trial Termination
核心洞察
InflaRx (搜索)'s Phase 3 trial of vilobelimab in pyoderma gangrenosum (搜索) was terminated early due to futility, but post-hoc analyses revealed positive treatment signals with significant ulcer volume reduction.
The study showed vilobelimab achieved a 45.4% reduction in target ulcer volume compared to placebo (p=0.0428) and significant improvements from Week 14 to Week 26.
Despite missing the primary endpoint, secondary analyses suggest vilobelimab may provide clinical benefit in this rare inflammatory skin disease with no FDA-approved therapies.
InflaRx (搜索) N.V. has disclosed detailed analyses from its terminated Phase 3 trial of vilobelimab in pyoderma gangrenosum (搜索) (PG), revealing encouraging signals of efficacy despite the study's early discontinuation due to futility. The post-hoc analyses suggest the complement C5a (搜索) inhibitor may offer clinical benefit in this rare inflammatory skin condition that currently has no FDA-approved treatments.
The Phase 3 study, which enrolled 54 patients before termination, failed to meet its primary endpoint of complete target ulcer closure on two consecutive visits. However, subsequent analyses revealed statistically significant improvements in ulcer volume reduction, with vilobelimab demonstrating an average 45.4% reduction compared to placebo across all visits from weeks 2-26 (p=0.0428).
Significant Treatment Effects Emerge in Secondary Analyses
The most compelling evidence came from mixed model repeated measures (MMRM) analyses, which showed consistent treatment differences favoring vilobelimab from Week 14 through Week 26. At Week 14, vilobelimab achieved a 57.6% reduction in ulcer volume versus placebo (p=0.0357), improving to 63.2% by Week 26 (p=0.0122).
Additional analyses of covariance (ANCOVAs) examining percentage changes from baseline in both volume (p=0.0111) and area (p=0.0072) from Week 12 to Week 26 also favored vilobelimab. These findings suggest that treatment duration beyond the six-month study period might yield even greater therapeutic benefits.
The primary endpoint showed vilobelimab achieving complete target ulcer closure in 20.8% of patients versus 16.7% for placebo, though this difference was not statistically significant. Secondary endpoints including complete disease remission showed improvement with vilobelimab (20.8% versus 5.6% for placebo), and more patients achieved greater than 50% reduction in target ulcer volume at week 26 (36.4% versus 16.7%).
Expert Commentary Supports Continued Development
"I am encouraged by the signals of efficacy observed from the Phase 3 post-hoc analyses of vilobelimab in pyoderma gangrenosum (搜索)," said Alex G. Ortega Loayza, MD, Professor and Interim Chair, Department of Dermatology at Oregon Health and Science University. "The role of targeting C5a (搜索)/C5aR (搜索) aligns with prior mechanistic work supporting its use for this devastating inflammatory dermatological disease, which has no FDA-approved therapy."
Benjamin Kaffenberger, MD, Associate Professor of Dermatology at The Ohio State University Wexner Medical Center, emphasized the challenges inherent in studying this rare condition. "The data for vilobelimab suggest an overall treatment effect, even if the primary endpoint may not have been achieved within the six-month timeframe required in this first-of-its-kind Phase 3 trial," he said. "I believe the futility leading to early discontinuation relates to challenges in trial design rather than lack of efficacy of the therapy."
Safety Profile Remains Favorable
Vilobelimab demonstrated a well-tolerated safety profile throughout the study. Treatment-emergent adverse events were predominantly mild to moderate, with serious related adverse events occurring in 6.3% of vilobelimab-treated patients compared to 4.5% in the placebo group. Patients also reported improved quality of life, with a 31.1% improvement in Dermatology Life Quality Index scores compared to a 3.4% worsening in the placebo group.
Regulatory Path Forward Requires Partnership
InflaRx (搜索) CEO and Founder Prof. Niels C. Riedemann noted that the study represented "the first randomized placebo-controlled study in pyoderma gangrenosum (搜索) using complete target ulcer closure on two consecutive visits as a stringent primary clinical endpoint, which has not been tested before in this rare disease."
The company plans to meet with the FDA to discuss potential alternative development pathways, including the use of different endpoints that might better capture vilobelimab's therapeutic effects. However, InflaRx (搜索) indicated it would only pursue future PG development in collaboration with a partner, as the company prioritizes resources for its oral C5aR (搜索) inhibitor izicopan (搜索) (INF904).
Mechanism of Action Shows Promise
Vilobelimab is a first-in-class monoclonal antibody that specifically targets complement factor C5a (搜索), a key inflammatory mediator. Unlike therapies that block C5 entirely, vilobelimab preserves the formation of the membrane attack complex (C5b-9), maintaining an important innate immune defense mechanism while selectively inhibiting C5a (搜索)-driven inflammation.
The post-hoc analyses provide compelling evidence that targeting the C5a (搜索)/C5aR (搜索) pathway may offer meaningful clinical benefit for patients with pyoderma gangrenosum (搜索), a neutrophilic inflammatory skin disease with significant unmet medical need. While the primary endpoint was not achieved within the study's timeframe, the consistent signals of efficacy across multiple secondary measures suggest vilobelimab's potential therapeutic value in this challenging indication.